中文版English

Home | Add to Favorites | Contact Us

About IMM

Academic Journals

Home >> About IMM >> Introduction

 

The Institute of Materia Medica (IMM) at Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) was founded in 1958. Its mandate is to discover and research innovative drugs for treating or preventing human diseases. IMM’s scientists use the latest biomedical theories, cutting-edge technologies, and state-of-the-art equipments to develop drugs from botanical compounds, synthetic chemicals, and bioproducts.

Principle drug research efforts at IMM focus on cancer, cardiovascular diseases, neurodegenerative and psychiatric diseases, metabolic disorders, infectious diseases, and inflammation. IMM researchers have made significant contributions in phytochemistry, analytic chemistry, computer-aided drug design, molecular pharmacology, high-throughput screening, synthetic biology, and drug-delivery systems. IMM has had notable successes in developing new drugs that serve patients in China and abroad.

The institute hosts the State Key Laboratory of Bioactive Substances and Functions of Natural Medicines and seven ministry-level key laboratories. The departments in IMM include synthetic medicinal chemistry, natural medicinal chemistry, pharmacology, pharmaceutical analysis, biosynthesis, drug screening, polymorphic drugs, drug delivery systems, drug metabolism, and new drug research and development. The Comprehensive Drug Platform funded by the National Science and Technology Major Project for New Drug Innovation and Development is one of the very few state drug programs established by China’s central government.

The institute has 500 faculty and staff members, of whom 145 are full or associate professors. Five scientists are academicians of the Chinese Academy of Sciences or the Chinese Academy of Engineering. IMM is housed on the main campus of the PUMC School of Pharmacy and provides training for senior pharmaceutical professionals and postdoctoral scientists. The Ministry of Education has classified pharmaceutical sciences at IMM as a national key discipline in medicine. IMM currently has nearly 400 graduate students and has trained 1,604 students to date, granting 835 doctoral and 769 Master’s degrees.

Since the institute’s establishment, its scientists have discovered or developed hundreds of new drugs and acquired 130 new drug certificates from the China Food and Drug Administration, including 21 innovative drugs such as butylphthalide, bicyclol and imrecoxib. IMM’s contributors have won 235 awards from the government and professional societies for drug research and development, including 31 at the national level. IMM has published more than 160 academic papers per year and 354 monographs, and holds 344 approved patents.

IMM focuses attention on translational research and development, and has two wholly owned enterprises: Beijing Union Pharmaceutical Factory and Beijing Union Second Pharmaceutical Factory. It is also the major shareholder of Beijing Lianxin Pharmaceutical Co. Ltd., Beijing Union-Genius Pharmaceutical Technology Co. Ltd., and Beijing Collab Pharma Co. Ltd..

IMM has established extensive partnerships in collaboration with pharmaceutical companies, universities, and research institutes worldwide, including in the United States, France, Japan, Germany, Spain, and Canada. Since 1989, IMM has established a collaboration with the Xinjiang Institute of Materia Medic, launching a new research facility called Xinjiang Branch of IMM, CAMS. The goal of this action is to cooperatively promote drug R&D of the minority medicine in Xinjiang.

IMM hosts editorial offices of four scientific journals: Acta Pharmaceutica Sinica, Chinese Chemical Letters, Journal of Asian Natural Products Research, and Acta Pharmaceutica Sinica B.

In the spirit of its motto, “Devotion, Innovation, Truth-Seeking, and Cooperation”, staff and faculty at IMM look forward to continuing their tradition of excellence in research, creating a sustainable future for new medicine and the Chinese health care industry.

 

 

 

 

 

 

 

 

【Back】